诺莫格拉姆可以预测年轻成年人急性缺血性中风的3个月预后
Qian He1,2, Miaoran Wang3, Haoyue Zhu2
1Qionglai Traditional Chinese Medicine Hospital, Chengdu, China.
Frontiers in neurology
|February 14, 2025
概括
这项研究开发了一种名谱,用于预测急性缺血性中风 (AIS) 的年轻成年人的3个月不良结果. 以前的中风和血压等因素有助于评估风险,以更好地管理患者.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 生物统计学 生物统计学
背景情况:
- 患有急性缺血性中风 (AIS) 的年轻人在预测长期结果方面面临着独特的挑战.
- 现有的风险分层模型可能无法完全捕捉影响这一人口群体恢复的具体因素.
研究的目的:
- 开发和验证AIS诊断的年轻成年人3个月不良结果的预测性名录.
- 确定关键的临床和人口因素,与这个患者群体的不良预后相关.
主要方法:
- 对1,015名患有AIS的年轻成年人 (18-50岁) 的回顾性研究.
- 利用后勤回归来识别预后因素并构建一个名ogram.
- 使用ROC曲线,校准图和决策曲线分析 (DCA) 评估模型性能.
主要成果:
- 确定了3个月不良结果的显著预测因素:家族中风史,先前的中风,先前的心脏病,烤面包类型,入院mRS得分,药物坚持,静脉血压 (SBP) 和乳酸脱酶 (LDH).
- 开发的名图表显示出优异的区分和校准性能.
- DCA证实了名图的临床实用性和适用性,用于风险预测.
结论:
- 纳入性别,家族中风病史,先前的中风,先前的心脏病,烤面包类型,入院mRS,药物坚持,SBP和LDH的名图可以有效地预测患有AIS的年轻成年人的3个月不良结果.
- 该工具有助于针对年轻的AIS患者进行个性化风险评估和临床决策.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
01:19Mitral Valve Prolapse III: Nursing Management
594
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
594
01:25Aortic Regurgitation III: Medical Management
599
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
599
01:30Acute Coronary Syndrome III: Diagnostic Studies
502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
01:29Acute Kidney Injury III: Clinical Manifestations
1.8K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K